Research programme: recombinant human hyaluronidases - Halozyme

Drug Profile

Research programme: recombinant human hyaluronidases - Halozyme

Alternative Names: HTI 201; HTI 401

Latest Information Update: 17 Dec 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Halozyme Therapeutics
  • Class Glycoside hydrolases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Inflammation; Metabolic disorders; Neurological disorders; Wounds

Most Recent Events

  • 08 Dec 2008 Halozyme licenses exclusive, global rights to Roche, for use of Enhanze technology with biologics, directed against fourth Roche target
  • 20 Dec 2006 rHuPH20 has been licensed for application to three predefined Roche biological targets
  • 14 Jul 2006 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top